MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

PKI-402

CAS No. : 1173204-81-3

MCE 站：PKI-402

产品活性：PKI-402 是一种有效的 PI3K 和 mTOR 抑制剂，抑制 PI3Kα, mTOR, PI3Kβ, PI3Kδ 和 PI3Kγ，IC₅₀ 分别为 2, 3, 7, 14 和 16 nM。

研究领域：PI3K/Akt/mTOR

作用靶点：PI3K  |  mTOR

In Vitro: PKI-402 is an equipotent inhibitor of class I PI3K, including the E545K and H1047R PI3K-α mutants (IC₅₀=2, 3 and 3 nM for PI3Kα, PI3Kα-H1047R and PI3Kα-E545K, respectively). PKI-402 causes in vitro growth inhibition of human tumor cell lines derived from a diverse set of human tumor tissues, including breast, brain (glioma), pancreas, and non-small cell lung cancer (NSCLC) tissues. PKI-402 inhibits MDA-MB-361 [breast: Her2⁺ and PIK3CA mutant (E545K)], with an IC₅₀ of 6 nM. PKI-402 inhibits HCT116 (K-Ras and PIK3CA mutant) with an IC₅₀ of 33 nM.

In Vivo: PKI-402 displays antitumor activity (i.v. route) in breast [MDA-MB-361: Her2⁺ and PIK3CA (E545K)], glioma (U87MG and PTEN), and NSCLC (A549; K-Ras and STK11) xenograft models. PKI-402 causes regression in the MDA-MB-361 xenograft model. PKI-402 effect is most pronounced at 100 mg/kg (daily for 5 days, one round), which reduces initial tumor volume and prevents tumor re-growth for 70 days. In MDA-MB-361 tumor tissue, PKI-402 at 100 mg/kg (single dose) fully suppresses p-Akt at both the T308 and the S473 sites at 8 hours and induces cleaved PARP. At 24 hours, p-Akt suppression is still evident, as is cleaved PARP.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Covalent Screening Library  |  Antioxidants Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Rapamycin  |  3-Methyladenine  |  LY294002  |  Wortmannin  |  Everolimus  |  MHY1485  |  Quercetin  |  740 Y-P  |  3BDO  |  Temsirolimus  |  Salidroside  |  Torkinib  |  PI-103  |  D-α-Hydroxyglutaric acid disodium  |  Isorhamnetin  |  L-Leucine  |  Recilisib  |  Autophinib  |  Dihydromyricetin  |  AZD 6482  |  PI3K-IN-1  |  TG100-115  |  α-Linolenic acid  |  TGX-221  |  1-Deoxynojirimycin  |  YS-49  |  AS-605240  |  Disitertide  |  Erucic acid  |  Polyphyllin I

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。